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Abstract
Background: Value-based health care has been proposed as a unifying force to drive
improved outcomes and cost containment.
Objective: Todevelop a standard set ofmultidimensional patient-centeredhealth outcomes
for tracking, comparing, and improving localized prostate cancer (PCa) treatment value.
rticipants: We convened an international working group of patients,
gists, and radiation oncologists to review existing data and practices.Keywords:
Outcome measurement
Design, setting, and pa
registry experts, uroloPatient-reported Outcome measurements and statistical analysis: The group deﬁned a recommended
ting who should be tracked, what should be measured and at what
at data are necessary to make meaningful comparisons. Using astandard set represen
time points, and wh1 These authors are co-ﬁrst authors.
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modiﬁed Delphi method over a series of teleconferences, the group reached consensus
for the Standard Set.
Results and limitations: We recommend that the Standard Set apply to men with
newly diagnosed localized PCa treated with active surveillance, surgery, radiation, or
other methods. The Standard Set includes acute toxicities occurring within 6 mo of
treatment as well as patient-reported outcomes tracked regularly out to 10 yr. Patient-
reported domains of urinary incontinence and irritation, bowel symptoms, sexual
symptoms, and hormonal symptoms are included, and the recommended measure-
ment tool is the Expanded Prostate Cancer Index Composite Short Form. Disease
control outcomes include overall, cause-speciﬁc, metastasis-free, and biochemical
relapse-free survival. Baseline clinical, pathologic, and comorbidity information is
included to improve the interpretability of comparisons.
Conclusions: We have deﬁned a simple, easily implemented set of outcomes that we
believe should be measured in all men with localized PCa as a crucial ﬁrst step in
improving the value of care.
Patient summary: Measuring, reporting, and comparing identical outcomes across
treatments and treatment centers will provide patients and providers with informa-
tion to make informed treatment decisions. We deﬁned a set of outcomes that we
recommend being tracked for every man being treated for localized prostate cancer.
# 2014 European Association of Urology. Published by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/3.0/).
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Localizedprostate cancer (PCa) represents themost common
noncutaneous malignancy afflicting men in Western coun-
tries, with a variety of management approaches including
surgery, radiation, and active surveillance that are widely
used. Variations in PCa outcomes have been observed based
on institutional and physician differences [1,2]. In the face of
increasing treatment costs [3] and with uncertain outcome
gains [4,5], value-based decisions about how, when, and
where to treat men with PCa are needed.
Value, defined as a patient’s outcomes divided by the
cost to achieve those outcomes, has been proposed as a
unifying force to improve care quality [6]. As part of an
integrated framework for reforming how care is delivered,
the need tomeasure value has become increasingly pressing
[7]. Key to measuring value is defining condition-specific
outcomes that matter to patients. These include disease
control, complications of treatment, and long-termquality of
life, although their relative importance varies among
individuals [8]. Outcome measures currently are inconsis-
tently collected and reported, limiting the direct population
comparisons necessary to improve value. This is particularly
true in the setting of patient-reported outcome measures
(PROMs), forwhichmanyvalidated instrumentsareavailable
for domains of urinary incontinence, urinary obstruction,
bowel irritation, and sexual dysfunction [9,10]. Efforts to
integrate both established disease control measures and
patient-reported outcomes (PROs) are taking place within
registries [11], but we do not yet have global standards for
which measures to include.
Systematic outcome measurements can guide institu-
tional improvements [12], foster dissemination of best
practices, and ultimately drive competition around value
[13]. We currently lack a common multidimensional
definition of the key outcomes for men with localized PCa
that physicians need to track to make meaningful compar-
isons. Using an international working group composed of
patients, registry representatives, urologists, and radiationoncologists, we undertook this project to define a set of
outcomes thatmatteredmost tomenwith localized PCa and
that we recommend all providers track.
2. Methods
The goal of this working groupwas to deﬁne a set of 10–15 key outcomes
and related risk factors, called the Standard Set, that should be tracked for
all patients with localized PCa in any country. We used a structured
consensus-driven modiﬁed Delphi method including a combination of
teleconferences and surveys to debate proposals based on evidence and
expert opinions from the project team and agreed to deﬁne the Standard
Set. From June to December 2013, the group convened for six
teleconferences, ﬁve of which were followed by surveys to gather
feedback and make decisions on the points discussed. The group used a
two-thirds threshold to determine when a particular point was decided.
The working groupwas convened and organized by the International
Consortium for Health Outcomes Measurement (ICHOM), a nonproﬁt
organization focused on the development of standard sets of outcomes
and risk factors by medical condition. Working group members were
invited to participate by peers from a smaller project team (N.M., L.M.,
C.S., M.G., and H.H.) that coordinated and led the group’s activities.
ICHOM had access to all the data during the project, but ICHOM, its
funders, and the funders of this project had no editorial control over the
ﬁnal publication.
3. Results
3.1. Condition scope
The Standard Set was designed around men with clinical
American Joint Committee of Cancer (AJCC) stages T1–T4
localized PCa treated with curative intent or followed with
active surveillance. Based on screening studies in the United
States and Europe, we believe this scope covers >90% of
men with newly diagnosed PCa [14,15]. A separate working
group has been convened to define relevant outcomes for
men with metastatic PCa.
3.2. Treatments
The treatments listed in Table 1 alone or in combination (eg,
radical prostatectomy followed by adjuvant external-beam
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set. We only included treatment details we believed were
essential for comparisons, and as a result, the treatments
are specified at the level of nerve sparing or non–nerve
sparing for surgery and the dose and fraction size for
radiation. We expect that centers will continue to collect
additional treatment-related and process details thatwould
be necessary for sharing best practices.
3.3. Survival and disease control
Knowledge of treatment efficacy is crucial for decision
making for most men with PCa [8]. We selected overall
survival, cause-specific survival, metastasis-free survival,
and biochemical recurrence–free survival as measures of
cancer eradication for the Standard Set. Although some of
these outcomes such as prostate-specific antigen (PSA)
recurrence are intermediate end points, they correlate
highly with patient anxiety and initiation of additional
therapy, warranting their inclusion in the set.
We recommend collecting survival and disease control
outcomes annually until death, recognizing this represents
a significant burden to many centers but is crucial to
understand the ultimate benefit of treatment.We recognize
that typical follow-up may eventually transfer back to
primary care physicians and salvage therapies may occur at
other facilities, and we advocate the development of health
information exchanges to track these outcomes across
settings. In their absence, institutions may need to collect
and abstract records from the currently treating institution
if the patient has transferred care.
3.4. Complications
Treatment complications are a central concern for patients
[8] and canhave a significant impact on long-termoutcomes.
Although many treatment-related toxicity scales exist, we
focused on those in common practice today. For nonsurgi-
cally treated patients, we selected the Common Terminology
Criteria forAdverseEvents (CTCAE)v.4. Thisgradingplatform
was designed as a comprehensive grading system for the
adverse effects of cancer treatment and is commonly used in
clinical trials. For surgically treated patients, we recommend
the Clavien-Dindo classification [16]. We suggest collecting
all grade 3 toxicities occurring within the first 6 mo
following local treatment alongwith the adverse event name
in the CTCAE.
3.5. Patient-reported health status
Given the frequency with which physicians underestimate
health-related quality of life in patients with PCa, PROMs
have been widely implemented [9,10]. Our goal was to
recommenda single PROMaddressing thepertinentdomains
to limit variability in assessment between treatment
modalities and centers. This was a contentious decision
because centers of excellence have established prospective
registries using various measures in PCa, and there is no
compelling evidence for the advantage of one particularPROM over another. However, to give clear advice to centers
and registries beginning their development, and in the hopes
of moving existing efforts toward alignment on measure
definitions over time, we included a consensus recommen-
dation for a single instrument: the Expanded Prostate Cancer
Index Composite 26-question short form (EPIC-26) [17].
Other excellent PROMs related to the outcomes follow-
ing PCa treatment exist [10,18–20], and our recommenda-
tion for centers not yet ready to switch to the EPIC-26, or for
centers with compelling reasons to use other validated
PROMs, would be to collect the same domains at the same
time points and develop cross-talk algorithms to allow
meaningful comparisons with those tracking the set. We
recognize that a 16-question version of EPIC designed for
easy implementation clinically has nowbeen validated [19],
but due to the absence of a question on rectal bleeding, an
important late toxicity from radiation, we continue to
recommend the 26-item questionnaire at present. We also
included three additional questions regarding sexual
interest and the use of sexual medication and devices in
the set to improve the interpretability of the sexual function
domain from the EPIC-26 (Table 1).
Men with PCa also frequently experience symptoms
outside the urinary, bowel, and sexual domains commonly
tracked that have an impact on their quality of life. A variety
of regularly used general health-related quality of life PROMs
exist including the EuroQOL five dimensions questionnaire
(EQ-5D), 12-item Short Form Health Survey (SF-12), Func-
tional Assessment of Cancer Therapy: General (FACT-G), and
the cancer-specific European Organization for Research and
Treatment of Cancer Quality of Life Questionnaire (QLQ-C30)
[21]. Ultimately, we did not feel themeasurement of general
health-related quality of life was an essential component of
the first version of this localized PCa set, andwe recommend
that interested centers consider using one such tool based on
their specific needs. We were also interested in including
specific measures for fatigue, anxiety, and time to return to
normal functioning. All are key outcomes associatedwith the
treatment of localized PCa but have not been commonly
integrated into general PCa PROMs. We advocate the
continued development of concise PROMs focused on these
domains for men with localized PCa.
We recommend assessing the PROs at baseline, prior to
treatment, at 6 mo following treatment, and then annually
at years 1–10 following treatment or until the development
of metastatic disease (Fig. 1). Although many of the side
effects of treatment are apparent in the first few years of
follow-up [9], changes in PROs have been observed with
longer term data collection [22]. In choosing 10 yr, we
attempted to balance the desire for complete follow-up
with cost and logistical concerns. We recognize that for
many centers and countries, it may be a long journey to
reach this goal.
The use of adjuvant versus salvage radiation following
prostatectomy remains controversial, and in this set, we
recommend continued collection of PROs in both situations.
Similarly, PROs after other salvage options such as
brachytherapy and surgery should be collected following
treatment.
Table 1 – Summary of the International Consortium for Health Outcomes Measurement Standard Set for localized prostate cancer
Measure Details Timing Data source
Treatment
approaches
included
Active surveillance At 6 mo after
treatment
initiation
Clinical data
abstraction
Watchful waiting
Radical prostatectomy* Nerve sparing or non–nerve
sparing
External-beam radiation therapy* Total dose and dose per
fractions
Brachytherapy* High- or low-dose rate
ADT* Was ADT part of the primary
treatment?
Focal therapy*
Other*
Baseline
characteristics
Age Date of birth Prior to
treatment
Administrative or
patient reported
Body mass index Height and weight Clinical data
Date of diagnosis Date of initial diagnosis Clinical data
Modiﬁed Charlson Comorbidity Index
questionnaire
Patient reported# Patient reported
PSA Most recent PSA value before
histologic diagnosis
Clinical data
AJCC 7th ed. clinical stage cT category, cN category, and
cM category
Clinical data
No. of biopsy cores involved No. of cores taken; no. of
cores positive
Clinical data
Greatest percentage involvement of biopsy
cores
Greatest percentage
involvement from biopsy
results
Clinical data
Biopsy Gleason score The highest primary and
secondary Gleason grade
Clinical data
AJCC 7th ed. pathologic stage pT category, pN category Following
surgery
Clinical data
Margin status Negative/Positive (if positive,
focal/multifocal)
Clinical data
Prostatectomy Gleason score The highest primary and
secondary Gleason grade
Clinical data
Acute
complications
(within 6 mo
of treatment)
Surgery patients: Clavien classiﬁcation Presence or absence of
grade 3
At 6 mo after
treatment
initiation
Clinical or patient
reported
Radiation patients: CTCAE classiﬁcation Presence or absence of grade
3 including name of the
adverse event
Survival and
disease control
Overall survival Date of death Evaluated at
least annually
until death
Administrative
data
Cause-speciﬁc survival Was death attributed to
prostate cancer on death
certiﬁcate?
Administrative
data
Metastasis-free survival Indicated date of metastatic
disease if applicable and
whether it was diagnosed
clinically or radiographically
Clinical or patient
reported
Biochemical recurrence–free survival Indicate date of PSA
recurrence if applicable
All PSAs and dates following
treatment should be
recorded
Clinical or patient
reported
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Table 1 (Continued )
Measure Details Timing Data source
Patient-reported
health status
Urinary incontinence domain scores EPIC-26 urinary incontinence
domain
At baseline,
6 mo after
treatment, and
then annually
following
treatment until
10 yr or the
diagnosis of
metastatic
disease
Patient reported
Urinary irritative/Obstructive scores EPIC-26 urinary irritative/
obstructive domain
Bowel symptom scores EPIC-26 bowel domain
Sexual symptom scores EPIC-26 sexual domain; two
additional questions from
EORTC QLQ-PR25 scale and
one from validated scale on
erectile dysfunction aids
Hormonal symptom scores (for men receiving
ADT)
EPIC-26 hormonal domain
ADT = androgen-deprivation therapy; AJCC = American Joint Committee on Cancer; CTCAE = Common Terminology Criteria for Adverse Events;
EORTC = European Organization for Research and Treatment of Cancer; EPIC = Expanded Prostate Cancer Index Composite; PSA = prostate-speciﬁc antigen;
QLQ-PR25 = Quality of Life Questionnaire-Prostate Module.
* These should also be collected as salvage treatments as necessary.
# ‘‘Have you ever been told by a doctor that you have any of the following? Heart disease (eg, angina, heart attack, or heart failure), high blood pressure, leg pain
when walking due to poor circulation, lung disease (eg, asthma, chronic bronchitis, or emphysema), diabetes, kidney disease, liver disease, problems caused by
stroke, disease of the nervous system (eg, Parkinson disease or multiple sclerosis), other cancer (within the last 5 yr), depression, arthritis, HIV/AIDS?’’ (yes or no
to each) [24].
(1)‘‘During the last 4 wk, to what extent were you interested in sex?’’ (not at all, a little, quite a bit, verymuch) [20], (2) ‘‘Have you used anymedications or devices
to aid or improve erections?’’ (yes, no), and (3) ‘‘For each of the following medications and devices, please indicate whether or not you have tried or currently
use it to improve your erections: Viagra or other pill, Muse (intraurethral alprostadil suppository), penile injection therapy (such as Caverject), vacuum erection
device (such as ErecAid), other’’ (have not tried it; tried it, but it was not helpful; it helped, but I am not using it now; it helped and I use it sometimes; it helped
and I use it always) [26].
[(Fig._1)TD$FIG]
Fig. 1 – Selected sample timelines illustrating when particular outcomes and baseline factors should be collected for patients treated with different
modalities including (a) surgery, (b) active surveillance followed by radiation, and (c) surgery with adjuvant radiation. These timelines are intended to
represent the outcome data collection points for possible treatment paths that a patient could take; they are not intended to advocate a particular
treatment approach.
PROMS = patient-reported outcome measures.
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Baseline clinical and pathologic factors are associated with
both disease control and quality of life outcomes in PCa.
Outlined in Table 1, the working group identified the
baseline data necessary to make meaningful comparisons
between patients. Numerous factors are associated with
clinical outcomes following treatment for PCa, and the
group focused on collecting established factors including
PSA level, Gleason score, number of positive cores, and the
percentage involvement of the core. Recognizing the long
natural history of localized PCa and the high relative rate of
death fromother causes, measures of comorbiditywere also
included [23]. The working group recommended the use of
the body mass index and a modified patient-reported
Charlson Comorbidity Index (CCI) questionnaire to collect
a list of comorbid diseases. A similar version has been
shown to correlatewell with a physician-reported CCI [24],
and the decision to select this tool as opposed to other
established measures was made in part pragmatically to
avoid reliance on claims or clinically abstracted data for
comorbidities. We recommend that these risk data be
collected before treatment initiation. For men undergoing
radical prostatectomy, additional pathologic data includ-
ing stage, Gleason score, and margin status should be
collected after surgery.
3.7. Data collection
A very important long-term goal of this effort is to produce
data that can be easily compared between providers,
centers, and countries. To achieve this, we recommend
processes to reduce variability including the use of similar
data sources, recognizing that the specific details of data
collection will necessarily differ by center. As outlined in
Table 1, the potential sources include claims data and death
registries, patient-reported sources, and clinical abstraction
or physician-reported sources, and we recommend that the
source of data as well as the response rate (if patient
reported) be tracked for every measure.
The Standard Set is consistentwith a data dictionary from
a registry, but in the face of regulatory, privacy, and
information technology challenges,we advocate that centers
without a national registry track these data individually
with the anticipation that future efforts led by ICHOM will
facilitate standardized comparisons between centers mea-
suring this set.
A data collection manual that further describes each
measure, its definition, inclusion and exclusion criteria, and
potential data sources is available on the ICHOM Web site
(www.ichom.org/project/localized-prostate-cancer).
4. Discussion
Value-based health care has the potential to align patients,
providers, and payers toward the common goal of improv-
ing outcomes and lowering costs. A current barrier to its
adoption is the absence of standardized outcomes that are
meaningful to patients [25]. We convened a working groupcomposed of patients, registry experts, urologists, and
radiation oncologists to define a standard set of outcomes
and risk factors that should be measured for all men with
localized PCa.
This cross-disciplinary effort should improve the
consistency of data we present to patients as they
approach decisions regarding treatment. This was an
important goal for our working group because it recog-
nizes the difficulties and uncertainties men face at the
time of diagnosis. We acknowledge that randomized
studies remain the gold standard for outcome compar-
isons between treatments, but registries serve as essential
companion efforts to assess the effectiveness of treat-
ments in real-world settings. As a minimum set, we
acknowledge that this effort cannot address all potentially
important variability including Gleason interpretation,
PSA assay variability, and all pertinent treatment details.
This project was made dramatically easier by a broad and
deep literature focused on PROs following treatment of
localized PCa. In fact, this breadth and depth challenged us to
pick from a variety of excellent PROMs and outcome
definitions. With an aim at parsimony, commonly used tools
like the International Prostate Symptom Score and Interna-
tional Index of Erectile Function were not included because
these domains are covered by the EPIC-26. Many practices
routinelyuse these andotherPROMsaspartof regular clinical
care, and we recognize that switching to or adding the EPIC-
26 may cause some disruption in longitudinal data. We
advocate future work to make commonly used PCa PROMs
comparable, allowing for a more seamless transition to a
universal standard.
Computer-adaptive PROMs are under investigation cur-
rently and may ultimately replace approaches such as the
EPIC-26, for which men are asked questions regardless of
whether they affirm to have symptoms in a specific domain.
We recognize that widespread adoption will also require
PROM translations to ensure comparability across popula-
tions.
Broad adoption of this Standard Set will also enable a
global network of providers to learn from each other by
comparing meaningful differences in the outcomes for their
patients. Existing observational data showwide variations in
PCa outcomes based on institutional and physician differ-
ences and suggest significant room for improvement [1,2].
We recognize that in many countries, significant financial
and logistical challenges remain to collect the various forms
of outcome data: administrative, patient-reported, and
abstracted data. However, recent investments in registry
infrastructure, such as those in Ireland, Canada, Australia, and
the United States, and increased focus on leveraging health
information technology investments for quality reporting
suggest that these barriers will become less significant over
time.
5. Conclusions
Through the efforts reported in this paper, we have defined
a relatively simple, easily implemented set of outcomes that
we believe should be measured in all men with localized
E U RO P E AN URO LOGY 6 7 ( 2 0 1 5 ) 4 6 0 – 4 6 7466PCa. This is a first step in an effort to drive what we hope are
meaningful and significant improvements in the care of all
men with this common disease.
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